Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors
Standard
Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. / Dum, David; Taherpour, Noushin; Menz, Anne; Höflmayer, Doris; Völkel, Cosima; Hinsch, Andrea; Gorbokon, Natalia; Lennartz, Maximilian; Hube-Magg, Claudia; Fraune, Christoph; Bernreuther, Christian; Lebok, Patrick; Clauditz, Till S; Jacobsen, Frank; Sauter, Guido; Uhlig, Ria; Wilczak, Waldemar; Steurer, Stefan; Minner, Sarah; Marx, Andreas H; Simon, Ronald; Burandt, Eike; Krech, Till; Luebke, Andreas M.
in: PATHOBIOLOGY, Jahrgang 89, Nr. 4, 2022, S. 245-258.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors
AU - Dum, David
AU - Taherpour, Noushin
AU - Menz, Anne
AU - Höflmayer, Doris
AU - Völkel, Cosima
AU - Hinsch, Andrea
AU - Gorbokon, Natalia
AU - Lennartz, Maximilian
AU - Hube-Magg, Claudia
AU - Fraune, Christoph
AU - Bernreuther, Christian
AU - Lebok, Patrick
AU - Clauditz, Till S
AU - Jacobsen, Frank
AU - Sauter, Guido
AU - Uhlig, Ria
AU - Wilczak, Waldemar
AU - Steurer, Stefan
AU - Minner, Sarah
AU - Marx, Andreas H
AU - Simon, Ronald
AU - Burandt, Eike
AU - Krech, Till
AU - Luebke, Andreas M
N1 - © 2022 S. Karger AG, Basel.
PY - 2022
Y1 - 2022
N2 - INTRODUCTION: Trophoblast cell surface antigen 2 (TROP2) is the target of sacituzumab govitecan, an antibody-drug conjugate approved for treatment of triple negative breast cancer and urothelial carcinoma.METHODS: A tissue microarray containing 18,563 samples from 150 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by TROP2 immunohistochemistry.RESULTS: TROP2 positivity was found in 109 tumor categories, including squamous cell carcinomas of various origins, urothelial, breast, prostate, pancreatic, and ovarian cancers (>95% positive). High TROP2 expression was linked to advanced stage (p = 0.0069) and nodal metastasis (p < 0.0001) in colorectal cancer as well as to nodal metastasis in gastric adenocarcinoma (p = 0.0246) and papillary thyroid cancer (p = 0.0013). Low TROP2 expression was linked to advanced stage in urothelial carcinoma (p < 0.0001), high pT (p = 0.0024), and high grade (p < 0.0001) in breast cancer, as well as with high Fuhrmann grade (p < 0.0001) and pT stage (p = 0.0009) in papillary renal cell carcinomas.CONCLUSION: TROP2 is expressed in many epithelial neoplasms. TROP2 deregulation can be associated with cancer progression in a tumor-type dependent manner. Since anti-TROP2 cancer drugs have demonstrated efficiency, they may be applicable to a broad range of tumor entities in the future.
AB - INTRODUCTION: Trophoblast cell surface antigen 2 (TROP2) is the target of sacituzumab govitecan, an antibody-drug conjugate approved for treatment of triple negative breast cancer and urothelial carcinoma.METHODS: A tissue microarray containing 18,563 samples from 150 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by TROP2 immunohistochemistry.RESULTS: TROP2 positivity was found in 109 tumor categories, including squamous cell carcinomas of various origins, urothelial, breast, prostate, pancreatic, and ovarian cancers (>95% positive). High TROP2 expression was linked to advanced stage (p = 0.0069) and nodal metastasis (p < 0.0001) in colorectal cancer as well as to nodal metastasis in gastric adenocarcinoma (p = 0.0246) and papillary thyroid cancer (p = 0.0013). Low TROP2 expression was linked to advanced stage in urothelial carcinoma (p < 0.0001), high pT (p = 0.0024), and high grade (p < 0.0001) in breast cancer, as well as with high Fuhrmann grade (p < 0.0001) and pT stage (p = 0.0009) in papillary renal cell carcinomas.CONCLUSION: TROP2 is expressed in many epithelial neoplasms. TROP2 deregulation can be associated with cancer progression in a tumor-type dependent manner. Since anti-TROP2 cancer drugs have demonstrated efficiency, they may be applicable to a broad range of tumor entities in the future.
U2 - 10.1159/000522206
DO - 10.1159/000522206
M3 - SCORING: Journal article
C2 - 35477165
VL - 89
SP - 245
EP - 258
JO - PATHOBIOLOGY
JF - PATHOBIOLOGY
SN - 1015-2008
IS - 4
ER -